ACR-2316 advances into dose expansion portion of Ph 1/2 study in SCLC, squamous NSCLC, lung adenocarcinoma (adNSCLC), endometrial, cervical, and GEJ cancers
“Advancing ACR-2316 into dose expansion is an important milestone for Acrivon, and the exciting initial clinical activity observed represents further clinical validation of our AP3 platform,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president and co-founder of Acrivon. “We rationally designed ACR-2316 using AP3 to overcome the resistance mechanisms that limit efficacy of single-target WEE1 and PKMYT1 inhibition, hence enabling potent tumor cell death. We are highly encouraged by the durable single-agent activity, including tumor shrinkage and PRs, and clinical benefit observed for more than a year in multiple heavily pretreated subjects with lung cancer. These data support our belief that ACR-2316 has the potential to become an important therapy across multiple high unmet need patient populations.”
Share:
More News
“This collaboration with Daiichi Sankyo represents an exciting milestone for our hematology franchise. Innovent has continued to expand its product footprint in this field, building a diversified portfolio and strong market presence including TYVYT® (sintilimab injection), HALPRYZA® (rituximab injection), olverembatinib, FUCASO® (Equecabtagene Autoleucel Injection), Jaypirca® (pirtobrutinib), and the addition of
“The initiation of our global Phase 3 program marks an important milestone for BL-M14D1 and reflects our commitment to bringing innovative treatment options to patients with small cell lung cancer,” said Jonathan Cheng, M.D., Chief Medical Officer of SystImmune. “Despite recent advances, outcomes for patients with extensive-stage small cell lung
Dr. Michael Ge, CEO of Kelun-Biotech, said, “Following the approval of sac-TMT for second-line or later treatment of TNBC based on results from the Phase III OptiTROP-Breast01 study, we are delighted to see another important milestone in the same disease area. For patients with PD-L1-negative advanced TNBC, the efficacy of
Dr. Shawn M. Leland, PharmD, RPh, Board Chairman of Evexta Bio stated: “We are very pleased and excited to partner with Roche on Evexta Bio’s first clinical collaboration with rupitasertib. ER+, HER2-, ESR1-mutated breast cancer remains a significant unmet medical need. We are looking forward to being able to provide